Mark Cuban Says Cutting PBM Fees Won't Reduce Pharmaceutical R&D Funding: 'Manufacturers Can Sell To Us For More'
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 01 2025
0mins
Source: Benzinga
Mark Cuban's Argument on PBMs: Billionaire Mark Cuban argues that reducing pharmacy benefit manager (PBM) fees could enhance pharmaceutical companies' profits, allowing for increased investment in research and development (R&D), challenging the notion that high drug prices are necessary for innovation.
Critique of PBMs: Cuban criticizes PBMs for inflating drug prices and limiting access to care, claiming they manipulate costs through rebates and fees, which ultimately detracts from funds available for R&D and innovation in the pharmaceutical industry.
Analyst Views on KURE
Wall Street analysts forecast KURE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KURE is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 18.130
Low
Averages
High
Current: 18.130
Low
Averages
High
No data
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
